Look for Drugs and Conditions

Remogliflozin etabonate

Remogliflozin etabonate

Remogliflozin, a novel, highly selective inhibitor of sodium-glucose cotransporter subtype 2 (SGLT2)

Indications

Type 2 diabetes mellitus


Dosage

oral; 100mg twice a day


Contra-Indications

Hypersensitivity


Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Data not sufficient Elderly: Data not sufficient


Side Effects

Low blood sugar (hypoglycemia), Urinary tract infections, Nervousness or anxiety, Irritability to sweat, Weight loss, Dizziness or headache, Fatigue, genital fungal infection


Drug Interactions

other hypoglycemic drugs


Other Combination Brands
Brand Name Manufactured by
REFOZI-M CARDIMIND PHARMACEUTICALS (A Division of Asterisk Laboratories Pvt Ltd)
Ad 5